Boston Scientific Corporation vs KB Financial Group, Inc. — how do they compare? Boston Scientific Corporation trades at $50.65 (market cap $74.19B), while KB Financial Group, Inc. trades at $118 (market cap $41.21B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and KB Financial Group, Inc. pays a 2.67% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | KB | |
|---|---|---|
Market Cap | $74.19B | $41.21B |
Sector | Health | Financials |
52-Week High | $108.14 | $124.01 |
52-Week Low | $42.63 | $77.50 |
Enterprise Value | $86.27B | — |
Dividend Yield | — | 2.67% |
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
KB Financial Group (KB) trades at $118.00, down 2.26% today, with a bullish technical signal from moving averages. The stock shows strong fundamental performance with consistent earnings beats, 27.82% net income margin, and attractive valuation at P/E of 10.36 and P/B of 0.98. Recent news highlights momentum potential and diversification into non-banking segments, which now contribute 43% of earnings.
Outlook remains positive with earnings growth and shareholder returns as key catalysts, though risks include volatile operating environment and heavy investing cash outflows. Analyst consensus leans cautious with 67% hold ratings, suggesting potential upside requires continued execution on diversification and fee income growth.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →